Antimicrobial resistance: a class effect?
暂无分享,去创建一个
J Prieto | A Calvo | M L Gómez-Lus | M. Gómez-Lus | J. Prieto | A. Calvo
[1] F. Baquero,et al. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). , 2000, The Journal of antimicrobial chemotherapy.
[2] P. Gilligan,et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] C. Cenjor,et al. In Vivo Efficacies of Amoxicillin and Cefuroxime against Penicillin-Resistant Streptococcus pneumoniae in a Gerbil Model of Acute Otitis Media , 1998, Antimicrobial Agents and Chemotherapy.
[4] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[5] T. File,et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. , 2002, The Journal of antimicrobial chemotherapy.
[6] I. Jado,et al. Short-Term Bactericidal Activity of Amoxicillin and Cefotaxime Against Penicillin-Susceptible and -Resistant Pneumococcal Strains: an In Vitro Pharmacodynamic Simulation , 2000, Journal of chemotherapy.
[7] R. Dal-Ré,et al. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation , 1996, Antimicrobial agents and chemotherapy.
[8] F. Baquero,et al. Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenesIsolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in Spain , 2001, Antimicrobial Agents and Chemotherapy.
[9] I. Klinar,et al. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. , 1997, Journal of chemotherapy.
[10] F. Baquero,et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. , 2001, The Journal of antimicrobial chemotherapy.
[11] M. Jones,et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.
[12] D. Felmingham,et al. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.
[13] J. Yuste,et al. Beta-lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model. , 2002, The Journal of antimicrobial chemotherapy.
[14] B. Aracil,et al. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998 , 2000 .
[15] P. Empey,et al. Levofloxacin Failure in a Patient with Pneumococcal Pneumonia , 2001, The Annals of pharmacotherapy.
[16] M. A. Gerber. Antibiotic resistance in group A streptococci. , 1995, Pediatric clinics of North America.
[17] F. Dunstan,et al. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8 , 1999, BMJ.
[18] G. Stefánsdóttir,et al. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study , 1996, BMJ.
[19] J. Jeljaszewicz,et al. Epidemiological aspects of antibiotic resistance in respiratory pathogens , 2001, International Journal of Antimicrobial Agents.
[20] F. Baquero. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? , 1999, Journal of chemotherapy.
[21] Á. Pascual,et al. Differences between Two New Quinolones (Gemifloxacin and Trovafloxacin) and Ciprofloxacin in Their Concentration-Dependent Killing of Streptococcus pneumoniae , 2001, Chemotherapy.
[22] F. Baquero,et al. Influences of Different Factors on Prevalence of Ciprofloxacin Resistance in Streptococcus pneumoniae in Spain , 2000, Antimicrobial Agents and Chemotherapy.
[23] E. Pérez-Trallero,et al. Prediction of In-Vivo Efficacy by In-Vitro Early Bactericidal Activity with Oral β-lactams, in a Dose-Ranging Immunocompetent Mouse Sepsis Model, Using Strains of Streptococcus pneumoniae with Decreasing Susceptibilities to Penicillin , 2001, Journal of chemotherapy.
[24] L. Aguilar,et al. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation. , 1999, Journal of chemotherapy.
[25] J. Oteo,et al. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. , 2001, The Journal of antimicrobial chemotherapy.
[26] R. Wise,et al. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. , 1999, The Journal of antimicrobial chemotherapy.
[27] C. Mcnulty. Optimising antibiotic prescribing in primary care. , 2001, International journal of antimicrobial agents.
[28] L. Aguilar,et al. Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: a phase I study , 1997, Antimicrobial agents and chemotherapy.
[29] K. Coleman,et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. , 2000, The Journal of antimicrobial chemotherapy.
[30] J. Dorca,et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. , 2001, Microbial drug resistance.
[31] F. Marco,et al. In Vitro Susceptibility to Gemifloxacin and Trovafloxacin of Streptococcus pneumoniae Strains Exhibiting Decreased Susceptibility to Ciprofloxacin , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[32] F. Baquero,et al. Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae , 2002, Journal of Clinical Microbiology.
[33] C. Cenjor,et al. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. , 2000, The Journal of infectious diseases.
[34] F. Sörgel,et al. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. , 2001, International journal of antimicrobial agents.
[35] M. Jones,et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. , 1999, The Journal of antimicrobial chemotherapy.
[36] F. Baquero,et al. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). , 2000, The Journal of antimicrobial chemotherapy.
[37] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[38] W. Graninger,et al. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network. , 1999, The Journal of antimicrobial chemotherapy.
[39] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[40] L. Aguilar,et al. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones. , 2001, The Journal of antimicrobial chemotherapy.
[41] F. Soriano,et al. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. , 1996, The Journal of antimicrobial chemotherapy.
[42] G. Woodnutt. Pharmacodynamics to combat resistance. , 2000, The Journal of antimicrobial chemotherapy.
[43] D E Low,et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.
[44] G. Drusano,et al. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. , 1997, Journal of chemotherapy.
[45] O. Cars,et al. Control of antimicrobial resistance: time for action , 1998, BMJ.